Mumps and mumps vaccine: a global review.

Authors: Galazka AM,Robertson SE,Kraigher A,
Address: National Institute of Hygiene, Warsaw, Poland.
Journal: Bull World Health Organ.

Publication: 1999;77(1):3-14.

abstract

mumps is an acute infectious disease caused by a paramyxovirus. Although the disease is usually mild, up to 10% of patients can develop aseptic meningitis; a less common but more serious complication is encephalitis, which can result in death or disability. Permanent deafness, orchitis, and pancreatitis are other untoward effects of mumps. Based on data reported to WHO up to April 1998, mumps vaccine is routinely used by national immunization programmes in 82 countries/areas: 23 (92%) of 25 developed countries, 19 (86%) of 22 countries with economies in transition (mainly the Newly Independent States of the former Soviet Union), and 40 (24%) of 168 developing countries. Countries that have achieved high coverage have shown a rapid decline in mumps morbidity. Furthermore, in many of these countries, mumps-associated encephalitis and deafness have nearly vanished. This review considers the disease burden due to mumps; summarizes studies on the immunogenicity, efficacy, and safety of different strains of mumps vaccine; and highlights lessons learned about implementing mumps immunization in different countries. Countries already using mumps vaccine should monitor immunization coverage and establish routine mumps surveillance with investigation of outbreaks. Where mumps is targeted for elimination, countries need to add a second dose of mumps vaccine for children, keeping in mind that the disease may still occur in susceptible adults.

PIP:

Mumps is an acute infectious disease caused by a paramyxovirus. While the disease is usually mild, up to 10% of patients can develop aseptic meningitis. A less common but more serious complication is encephalitis, which can result in death or disability. Permanent deafness, orchitis, and pancreatitis are other adverse effects of mumps. Based upon data reported to the World Health Organization (WHO) up to April 1998, mumps vaccine is routinely used by national immunization programs in 82 countries/areas: 23 of 25 developed countries, 19 of 22 countries with economies in transition, and 40 of 168 developing countries. Countries which have achieved high vaccine coverage have realized a rapid decline in mumps morbidity. Also in many such countries, mumps-associated encephalitis and deafness have almost vanished. The authors consider the disease burden due to mumps; summarize studies on the immunogenicity, efficacy, and safety of different strains of mumps vaccine; and note lessons learned about implementing mumps immunization in different countries. Countries already using mumps vaccine should monitor immunization coverage and establish routine mumps surveillance with investigation of outbreaks. Where mumps is targeted to be eliminated, countries need to add a second dose of mumps vaccine for children.

Related Articles
Review [Mumps--still actual epidemiological problem in Poland].
Przegl Epidemiol. 2005
Review [Mumps--still actual epidemiological problem in Poland].
Pogorzelska M, Ołdak E, Sulik A. Przegl Epidemiol. 2005; 59(4):841-9.
[Wide spread inflammation of the parotid glands (mumps): underestimated disease. I. Epidemiology of the mumps and its medical meaning in Poland].
Przegl Epidemiol. 1998
[Wide spread inflammation of the parotid glands (mumps): underestimated disease. I. Epidemiology of the mumps and its medical meaning in Poland].
Gałazka A, Kraigher A, Robertson SE. Przegl Epidemiol. 1998; 52(4):389-400.
Measles and mumps immunization: benefit versus risk factors.
Dev Biol Stand. 1979
Measles and mumps immunization: benefit versus risk factors.
Krugman S. Dev Biol Stand. 1979; 43:253-7.
One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
Pediatrics. 2006
One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?
Lopez AS, Guris D, Zimmerman L, Gladden L, Moore T, Haselow DT, Loparev VN, Schmid DS, Jumaan AO, Snow SL. Pediatrics. 2006 Jun; 117(6):e1070-7.
Review Mumps.
Lancet. 2008
Review Mumps.
Hviid A, Rubin S, Mühlemann K. Lancet. 2008 Mar 15; 371(9616):932-44.
Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines.
Iran Red Crescent Med J. 2012
Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines.
Shahkarami MK, Mokhtari Azad T, Aghaiypour K, Shafyi A, Taqavian M, Mohammadi A. Iran Red Crescent Med J. 2012 Sep; 14(9):508-14. Epub 2012 Sep 30.
Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.
PLoS One. 2012
Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.
Poethko-Müller C, Mankertz A. PLoS One. 2012; 7(8):e42867. Epub 2012 Aug 6.
Presumed cases of mumps in pregnancy: clinical and infection control implications.
Infect Dis Obstet Gynecol. 2012
Presumed cases of mumps in pregnancy: clinical and infection control implications.
Lozo S, Ahmed A, Chapnick E, O'Keefe M, Minkoff H. Infect Dis Obstet Gynecol. 2012; 2012:345068. Epub 2012 Feb 12.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.